Promising early results from pSivida uveitis trial
12 July, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) said none of the eyes treated using its micro-insert experienced a recurrence in posterior uveitis during the first 12 months of its phase I/II trial.
Protagonist raises $14m for peptide discovery
11 July, 2013 by Dylan Bushell-EmblingUniversity of Queensland-based Protagonist Therapeutics has closed a $14m financing round to support its disulfide rich peptide (DRP) discovery program.
Patrys, Minomic and Starpharma secure ARC grants
11 July, 2013 by Dylan Bushell-EmblingThe ARC has awarded fresh Linkage Grants for collaborations between Macquarie University, Patrys (ASX:PAB) and Minomic, and between Monash University and Starpharma (ASX:SPL).
Biotech boards and doing business in China feature in July AusBiotech journal
11 July, 2013AusBiotech is pleased to provide you with the latest edition of the Australasian Biotechnology e-journal (Volume 23, Number 2).
PolyNovo eyes plastic surgery market for NovoSorb
10 July, 2013 by Dylan Bushell-EmblingCalzada (ASX:CZD) unit PolyNovo is teaming up with a group of US specialists to develop and commercialise products for the plastic surgery market based on polymer technology Novosorb.
Student awards need a saviour
09 July, 2013The annual Student Excellence Awards, which support Australian students in bioscience research with reward and recognition, are in need of an industry sponsor if they are to go ahead this year.
Supporting industry innovation
09 July, 2013The $70,000 Australian Innovation Challenge awards are now open and seeking great ideas from Australians.
iSonea raises $13.5m to fund AirSonea launch
09 July, 2013 by Dylan Bushell-EmblingiSonea (ASX:ISN) has raised $13.5m in a placement to help pay the manufacturing, distribution and marketing costs of the upcoming launch of mobile wheeze-monitoring device AirSonea.
Bioniche closes funding, licensing deal with Paladin
08 July, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has gained access to a further C$5m in funding after closing its debt refinancing and Urocidin licensing deal with Paladin Labs.
Novogen gets up to $5m to fund CS-6 development
08 July, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has signed a deal with a US investor that will give it access to up to $5m in working capital to help take cancer drug candidate CS-6 into the clinic.
Pharmaxis, Phylogica and LBT win ARC grants
05 July, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS), Phylogica (ASX:PYC) and LBT Innovation (ASX:LBT) will all receive Australian Research Council linkage grants for projects with universities.
pSivida initiates posterior uveitis trial
04 July, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) has commenced recruitment for one of two planned US phase III trials of its injectable micro-insert in posterior uveitis.
Review of employee share schemes announced
04 July, 2013AusBiotech was pleased to learn that the government has announced it will review the policy settings around employee share schemes (ESS).
CSL progresses therapies for haemophilia
04 July, 2013A new group of therapies is showing promise for the treatment of haemophilia.
Phylogica advances collaboration with Janssen
02 July, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has identified peptide candidates in its drug-discovery collaboration with Janssen Biotech and will move on to exploring their functionality within cells.
